Widget

Add BioCurex widget to your own site or blog

Narrow [210x500]

Wide [800x150]

Copy and Paste the following code:

AGORACOM News Flash

AGORACOM CONFERENCE UPDATE

12 More Companies Added To Schedule For Dec 3 & 4. (See Schedule)
Keynote Speakers Include Peter Grandich, Eric Coffin (See Speakers)
Workshop Presentations Added To Thursday Schedule
Investors from over 45 Countries Have Visited
Conference Begins 2 Weeks From Today!

Looking forward to seeing all of you there gang. Registration is free for investors. AGORACOM Members register with just one click. Non-members takes less than 60 seconds. Register here (see form on right hand side)

Message: BioCurex Announces Shareholder Update

AGORACOM

Rank: [?]

Administrator

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

BioCurex Announces Shareholder Update

posted on May 01, 09 08:02AM

Note...

we thank "dude2" for his contribution to this board...

AGORACOM

RICHMOND, British Columbia, May 1, 2009 -- BioCurex Inc. (OTCBB:BOCX) wishes to communicate to its shareholders that certain note holders have agreed to grant the company an extension until May 14th in order to continue negotiations related to amendments in the terms of the agreements securing the notes.

This extension will allow the company to discuss - in advance - the new terms that it will present to the note holders with investors and/or investment groups that have expressed an interest in the company.

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for further information on these agreements see: http://sec.gov/Archives/edgar/data/1... ).

The cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

To read more about the Company, please visit the News section in our web site (www.biocurex.com).

Note:

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

CONTACT: BioCurex, Inc.
Ricardo Moro
(604) 207-9150